Pictet Asset Management SA decreased its position in Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Rating) by 90.5% in the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 12,400 shares of the biotechnology company’s stock after selling 118,320 shares during the period. Pictet Asset Management SA’s holdings in Pacific Biosciences of California were worth $55,000 at the end of the most recent quarter.
A number of other large investors have also recently modified their holdings of PACB. Versor Investments LP acquired a new position in shares of Pacific Biosciences of California during the second quarter worth $44,000. Interchange Capital Partners LLC acquired a new position in shares of Pacific Biosciences of California during the 1st quarter worth about $102,000. Integrity Advisory LLC acquired a new stake in Pacific Biosciences of California in the 1st quarter valued at about $103,000. Portland Investment Counsel Inc. acquired a new stake in Pacific Biosciences of California in the 1st quarter valued at about $109,000. Finally, Carret Asset Management LLC acquired a new stake in shares of Pacific Biosciences of California during the 2nd quarter worth approximately $53,000.
Analyst Upgrades and Downgrades
A number of equities analysts recently weighed in on PACB shares. Piper Sandler increased their price objective on shares of Pacific Biosciences of California from $6.00 to $11.00 in a research report on Wednesday, November 16th. Cowen reduced their price target on shares of Pacific Biosciences of California to $8.00 in a research report on Tuesday, August 9th. Finally, Canaccord Genuity Group upped their target price on shares of Pacific Biosciences of California from $12.00 to $14.00 in a report on Wednesday, November 16th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $18.40.
Insiders Place Their Bets
Pacific Biosciences of California Trading Down 2.5 %
Shares of PACB opened at $10.35 on Friday. The company has a current ratio of 11.19, a quick ratio of 10.66 and a debt-to-equity ratio of 1.43. The firm’s 50-day moving average is $7.64 and its two-hundred day moving average is $6.21. Pacific Biosciences of California, Inc. has a twelve month low of $3.85 and a twelve month high of $23.87. The firm has a market capitalization of $2.34 billion, a P/E ratio of -7.72 and a beta of 1.43.
Pacific Biosciences of California Company Profile
Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.
- Get a free copy of the StockNews.com research report on Pacific Biosciences of California (PACB)
- Microsoft Shares: Is it Time to Back Up the Truck?
- Institutional Support for Analog Devices Remains High
- Is the 60/40 Portfolio Mix Still in Vogue?
- Three CBD Stocks to Dominate a Budding Industry
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.